Wat is de prijs voor AbbVie Inc. (ABBV)

Het prijs van AbbVie Inc. (ABBV) is $263.25

Wat is de marktkapitalisatie voor AbbVie Inc. (ABBV)

Marktkapitalisatie voorAbbVie Inc. (ABBV) is $465.10B

AbbVie Inc. (ABBV) K/B-verhouding

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

Jaar	P/B-ratio	Wijzigen
2026 (TTM)	-78.09	-100.00%
2025	0.00	-100.00%
2024	94.54	257.48%
2023	26.45	59.43%
2022	16.59	6.65%
2021	15.55	13.87%
2020	13.66	-185.13%
2019	-16.05	-4.60%
2018	-16.82	-155.55%
2017	30.28	38.22%
2016	21.91	-10.22%
2015	24.40	-59.27%
2014	59.92	220.74%
2013	18.68	16.62%
2012	16.02	237.93%
2011	4.74	31.60%
2010	3.60	0.00%
2009	0.00	0.00%

Jaar

P/B-ratio

Wijzigen

2026 (TTM)

-78.09

-100.00%

2025

0.00

-100.00%

2024

94.54

257.48%

2023

26.45

59.43%

2022

16.59

6.65%

2021

15.55

13.87%

2020

13.66

-185.13%

2019

-16.05

-4.60%

2018

-16.82

-155.55%

2017

30.28

38.22%

2016

21.91

-10.22%

2015

24.40

-59.27%

2014

59.92

220.74%

2013

18.68

16.62%

2012

16.02

237.93%

2011

4.74

31.60%

2010

3.60

0.00%

2009

0.00

0.00%

Bedrijf	P/B-ratio	Verschil in P/B-ratio	Land
Eli Lilly and Company LLY.US	29.9692	-138.38%	US
Johnson & Johnson JNJ.US	7.6479	-109.79%	US
Roche Holding AG RO.SW	8.4776	-110.86%	CH
Merck & Co., Inc. MRK.US	8.5385	-110.93%	US
Novartis AG NOVN.SW	6.754	-108.65%	CH

Bedrijf

P/B-ratio

Verschil in P/B-ratio

Land